1
|
Yamashita S, Arai H, Yokote K, Araki E, Hounslow N, Ikeda K, Nojima T, Suganami H, Ishibashi S. Response of lipoproteins to a meal tolerance test in patients with type 2 diabetes and hypertriglyceridemia. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Nojima T, Matsubayashi Y, Yoshida A, Suganami H, Abe T, Ishizawa M, Fujihara K, Tanaka S, Kaku K, Sone H. Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. Diabet Med 2020; 37:1316-1325. [PMID: 32096571 PMCID: PMC7496771 DOI: 10.1111/dme.14279] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/22/2020] [Indexed: 12/12/2022]
Abstract
AIMS To examine the effects of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, tofogliflozin, on resting heart rate by exploring baseline factors that independently influenced changes in the resting heart rate. METHODS Data on 419 participants in tofogliflozin phase 2/3 trials were analysed. Changes in resting heart rate from baseline to week 24 were analysed using an analysis of covariance (ANCOVA) model with groups (tofogliflozin/placebo) as a fixed effect and baseline values as covariates. The antilipolytic effect was evaluated as adipose tissue insulin resistance (Adipo-IR) and was calculated as the product of fasting insulin and free fatty acid. Multivariate analysis evaluated independent factors for changes in resting heart rate from baseline to week 24. RESULTS Of the participants, 58% were men, and mean age, HbA1c , BMI and resting heart rate were 57.6 years, 65 mmol/mol (8.1%), 25.5 kg/m2 and 66 bpm, respectively. At week 24, adjusted mean difference vs. placebo in the change from baseline was -2.3 bpm [95% confidence interval (CI) -4.6, -0.1] with tofogliflozin. Changes in resting heart rate were positively correlated with changes in Adipo-IR, whereas reductions in HbA1c , body weight and blood pressure were similar independent of changes in resting heart among quartiles of resting heart rate change. On multivariate analysis, higher baseline resting heart rates and Adipo-IR values were significantly associated with greater reductions in resting heart rate. CONCLUSIONS Tofogliflozin corrected resting heart rate levels in accordance with baseline levels. Correction of high resting heart rates may be attributed to improved adipose tissue insulin resistance, leading to correction of hyperinsulinaemia.
Collapse
Affiliation(s)
- T. Nojima
- Department of Hematology, Endocrinology and MetabolismNiigata University Faculty of MedicineNiigataJapan
- Clinical Data Science DepartmentKowa Co., Ltd.TokyoJapan
| | - Y. Matsubayashi
- Department of Hematology, Endocrinology and MetabolismNiigata University Faculty of MedicineNiigataJapan
| | - A. Yoshida
- Department of Hematology, Endocrinology and MetabolismNiigata University Faculty of MedicineNiigataJapan
- Kowa Co., Ltd.TokyoJapan
| | - H. Suganami
- Clinical Data Science DepartmentKowa Co., Ltd.TokyoJapan
| | - T. Abe
- Department of Hematology, Endocrinology and MetabolismNiigata University Faculty of MedicineNiigataJapan
| | - M. Ishizawa
- Department of Hematology, Endocrinology and MetabolismNiigata University Faculty of MedicineNiigataJapan
| | - K. Fujihara
- Department of Hematology, Endocrinology and MetabolismNiigata University Faculty of MedicineNiigataJapan
| | - S. Tanaka
- Department of Clinical BiostatisticsGraduate School of MedicineKyoto UniversityKyotoJapan
| | - K. Kaku
- Kawasaki Medical SchoolOkayamaJapan
| | - H. Sone
- Department of Hematology, Endocrinology and MetabolismNiigata University Faculty of MedicineNiigataJapan
| |
Collapse
|
3
|
Matsubayashi Y, Yoshida A, Suganami H, Ishiguro H, Yamamoto M, Fujihara K, Kodama S, Tanaka S, Kaku K, Sone H. Role of fatty liver in the association between obesity and reduced hepatic insulin clearance. Diabetes Metab 2017; 44:135-142. [PMID: 29395810 DOI: 10.1016/j.diabet.2017.12.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 11/13/2017] [Accepted: 12/03/2017] [Indexed: 01/29/2023]
Abstract
AIM Hepatic insulin clearance (HIC) is important in regulating plasma insulin levels. Diminished HIC causes inappropriate hyperinsulinaemia, and both obesity and fatty liver (FL), which are known to decrease HIC, can be found either together in the same patient or on their own. The mechanism by which obesity reduces HIC is presumed to be mediated by FL. However, few reports have examined the role of FL in the relationship between obesity and HIC in type 2 diabetes (T2D) patients. Therefore, our study investigated the association of HIC with clinical factors, including insulin sensitivity indices, focusing on the presence or absence of FL and obesity in T2D patients. METHOD Baseline data from 419 patients with T2D (279 men, 140 women; mean age: 57.6 years; body mass index: 25.5kg/m2) controlled by diet and exercise were analyzed. HIC was calculated from the ratio of fasting c-peptide to fasting insulin levels (HICCIR). Correlation analyses between HICCIR and clinical variables were performed using Pearson's product-moment correlation coefficients and single regression analysis in all participants and in those with obesity and FL either alone or in combination. RESULTS HICCIR was significantly correlated with whole-body insulin sensitivity indices and influenced by FL, but only in the FL group was obesity independently influenced HIC level. HICCIR decreased in those with both FL and obesity compared with those with only one such complication. CONCLUSION HICCIR may be used to evaluate whole-body insulin sensitivity in T2D. Also, compared with obesity, the influence of FL strongly contributed to a reduced HIC. TRIAL REGISTRATION NUMBER These trials were registered by the Japan Pharmaceutical Information Centre clinical trials information (JapicCTI) as 101349 and 101351.
Collapse
Affiliation(s)
- Y Matsubayashi
- Department of hematology, endocrinology and metabolism, faculty of medicine, Niigata university, Niigata, Japan
| | - A Yoshida
- Department of hematology, endocrinology and metabolism, faculty of medicine, Niigata university, Niigata, Japan; Medical information and product advancement department, Kowa Pharmaceutical Co. Ltd, Tokyo, Japan
| | - H Suganami
- Clinical data science department, Kowa Co. Ltd, 3-4-10 Nihonbashi-Honcho, Chuo-ku, 103-0023 TokyoJapan
| | - H Ishiguro
- Department of hematology, endocrinology and metabolism, faculty of medicine, Niigata university, Niigata, Japan
| | - M Yamamoto
- Department of hematology, endocrinology and metabolism, faculty of medicine, Niigata university, Niigata, Japan
| | - K Fujihara
- Department of hematology, endocrinology and metabolism, faculty of medicine, Niigata university, Niigata, Japan
| | - S Kodama
- Department of hematology, endocrinology and metabolism, faculty of medicine, Niigata university, Niigata, Japan
| | - S Tanaka
- Department of clinical biostatistics, Graduate School of Medicine, Kyoto university
| | - K Kaku
- Kawasaki Medical School, Yoshida-konoe-cho, Sakyo-ku, 606-8501 KyotoOkayama, Japan
| | - H Sone
- Department of hematology, endocrinology and metabolism, faculty of medicine, Niigata university, Niigata, Japan.
| |
Collapse
|
4
|
Abe T, Matsubayashi Y, Yoshida A, Suganami H, Nojima T, Osawa T, Ishizawa M, Yamamoto M, Fujihara K, Tanaka S, Kaku K, Sone H. Predictors of the response of HbA1c and body weight after SGLT2 inhibition. Diabetes Metab 2017; 44:172-174. [PMID: 29128289 DOI: 10.1016/j.diabet.2017.10.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 10/03/2017] [Accepted: 10/08/2017] [Indexed: 02/04/2023]
Affiliation(s)
- T Abe
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - Y Matsubayashi
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - A Yoshida
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan; Medical Information and Product Advancement Department, Kowa Pharmaceutical Company Ltd., Tokyo, Japan
| | - H Suganami
- Clinical Data Science Department, Kowa Company Ltd., Tokyo, Japan
| | - T Nojima
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan; Clinical Data Science Department, Kowa Company Ltd., Tokyo, Japan
| | - T Osawa
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - M Ishizawa
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - M Yamamoto
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - K Fujihara
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
| | - S Tanaka
- Department of Clinical Biostatistics, Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Kaku
- Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan
| | - H Sone
- Department of Haematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
| |
Collapse
|
5
|
Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, Kitahara M, Hamakubo T, Kodama T, Saito Y. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2001; 7:138-44. [PMID: 11480454 DOI: 10.5551/jat1994.7.138] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
The effect of various 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on the induction of HMG-CoA reductase and low density lipoprotein (LDL) receptor mRNA were quantitatively determined in the cultured human hepatoma cell line Hep G2 by means of a ribonuclease protection assay. Lipophilic inhibitors including mevastatin, simvastatin, atorvastatin and NK-104 were able to increase the levels of mRNAs for HMG-CoA reductase and the LDL receptor, but the hydrophilic inhibitor pravastatin was not effective in Hep G2 cells as had previously been reported. The LDL receptor mRNA was induced by NK-104 most effectively between 0.1 to 10 microM among the lipophilic inhibitors, whereas the degrees of induction of HMG-CoA reductase mRNA by these inhibitors did not differ significantly from each other. When cells were treated with a 200-fold excess of the IC50 concentration of each inhibitor, NK-104 was able to induce LDL receptor mRNA most effectively. These results indicate that the effect of HMG-CoA reductase inhibitors on the upregulation of mRNA for reductase and LDL receptor are different from each other and among these lipophilic inhibitors. NK-104 is most effective in inducing LDL receptor mRNA in Hep G2 cells.
Collapse
Affiliation(s)
- S Morikawa
- Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Meguro, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, Kitahara M, Hamakubo T, Kodama T, Saito Y. The relative induction of mRNA for HMGCoA and LDL receptor by five different HMGCoA reductase inhibitors in cultured human cells. Atherosclerosis 2000. [DOI: 10.1016/s0021-9150(00)80165-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Wachi H, Seyama Y, Yamashita S, Suganami H, Uemura Y, Okamoto K, Yamada H, Tajima S. Stimulation of cell proliferation and autoregulation of elastin expression by elastin peptide VPGVG in cultured chick vascular smooth muscle cells. FEBS Lett 1995; 368:215-9. [PMID: 7628608 DOI: 10.1016/0014-5793(95)00641-l] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Synthetic elastin peptides, VPGVG or its polymer (VPGVG)n, enhanced the proliferation of smooth muscle cells 1.5-fold during 48 h treatment at the concentrations over 10(-6) M or 1.0 microgram/ml, respectively. Monomeric and polymeric VPGVG sequences reduced elastin synthesis and its mRNA level to one-third and one-half of control respectively under the conditions in which the proliferation of cells were enhanced, but did not change collagen synthesis as measured by bacterial collagenase digestion. The elastin-specific autoregulation by elastin fragments may reflect the feedback regulation of elastin expression which may play an essential role in elastin metabolism under the normal and diseased conditions.
Collapse
Affiliation(s)
- H Wachi
- Department of Clinical Chemistry, Hoshi College of Pharmacy, Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|